Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D010919:Placebos; D011720:Pyrazoles / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D013729:Terpenes / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D010919:Placebos; D011720:Pyrazoles; D013729:Terpenes; D010653:Phenylbutazone